
    
      This is a blinded, multi-center study to provide approximately 1 additional year of follow-up
      for patients with knee OA who participated in a randomized placebo-controlled study of IA
      UBX0101. No intervention is planned and patients will have 4 scheduled visits to collect
      follow-up assessments. The primary objective is to evaluate long-term safety and tolerability
      of IA administration of UBX0101 in patients with painful knee OA.
    
  